Community-acquired Pneumonia

CAP drug market to decline from $1.3 billion in 2001 to $1 billion in 2011

Published in TB and Outbreaks Week, October 22nd, 2002

Decision Resources, Inc., a research and advisory firm focusing on pharmaceutical and healthcare issues, announced that the saturated community-acquired pneumonia (CAP) drug market will decline from nearly $1.3 billion in 2001 to $1 billion in 2011.

A new Pharmacor report from Decision Resources, "Community-Acquired Pneumonia," concludes that generic erosion will be a major factor in the sales decrease.

"There are many drugs available to treat community-acquired pneumonia," said Margaret Jorgensen, PhD, analyst at Decision Resources. "Because of this market saturation, the growth potential of emerging agents to treat community-acquired pneumonia is...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2002-10-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry